Immune checkpoint inhibitors are already available in ESCC and are another promising candidate for multimodal treatment because strong PD-L1 expression is generally observed in esophageal cancers, with reported expression levels in the tumor cells of 15–83% and in immune cells of 13–31% [28,29,30,31]. The gene discussed is CD274; the disease is neoplasm.